{"id":58464,"date":"2024-02-27T18:37:02","date_gmt":"2024-02-27T18:37:02","guid":{"rendered":"https:\/\/medsname.com\/mirzacan\/"},"modified":"2026-04-30T10:24:13","modified_gmt":"2026-04-30T10:24:13","slug":"mirzacan","status":"publish","type":"product","link":"https:\/\/medsbase.com\/sv\/product\/mirzacan\/","title":{"rendered":"Mirzacan"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 Snabbt svar<\/h3>\n

Mirzacan (Mirtazapine 15 \/ 30 mg) is a tetracyclic antidepressant (NaSSA) for major depression, particularly when insomnia, anxiety, weight loss, or anorexia are dominant symptoms. Strongly sedating at low doses, less sedating at higher doses (counterintuitive \u2014 see below).<\/p>\n<\/div>\n

\nVad du f\u00e5r med MedsBase:<\/strong> WHO-GMP-certifierad tillverkare \u00b7 Diskret f\u00f6rpackning \u00b7 V\u00e4rldsvid leverans \u00b7 1 400+ verifierade kundrecensioner<\/a>\n<\/div>\n

\ud83d\udce6 Varje best\u00e4llning omfattas av v\u00e5r Reshipment Assurance Policy<\/strong><\/a> \u2014 om din f\u00f6rs\u00e4ndelse inte anl\u00e4nder inom 20 arbetsdagar, skickar vi om den.<\/p>\n

Varf\u00f6r best\u00e4lla fr\u00e5n MedsBase<\/h3>\n

Mirzacan at MedsBase is supplied directly from a WHO-GMP certified manufacturer in plain, discreet packaging. Every order is covered by our Reshipment Assurance Policy<\/a> \u2014 20 arbetsdagar leveranstid eller vi skickar om utan extra kostnad \u2014 och kvalificerar sig f\u00f6r v\u00e5rt kundlojalitetsprogram<\/a>. V\u00e4rldsomsp\u00e4nnande leverans \u00e4r tillg\u00e4nglig till de flesta destinationer.<\/p>\n

What Mirzacan is and how it works<\/h2>\n

Mirzacan is a 15 \/ 30 mg mirtazapine tablet supplied by Cadila. Mirtazapine is structurally and mechanistically distinct from SSRIs\/SNRIs\/TCAs. It is a noradrenergic and specific serotonergic antidepressant (NaSSA): it blocks central \u03b12-adrenergic autoreceptors (raising NA and 5-HT release indirectly), 5-HT2A and 5-HT2C receptors (anxiolytic, sleep-promoting, no sexual dysfunction), and H1 histamine receptors (sedation and appetite stimulation).<\/p>\n

\nCounterintuitive dose-sedation curve<\/strong><\/p>\n

At 7.5\u201315 mg, mirtazapine is most sedating. At 30 mg+, the noradrenergic component (which is more linearly dose-related than the H1 antihistaminergic component) starts to offset the H1 sedation. Many patients describe 30 mg as “feeling more energised” than 15 mg. If a patient wants more sleep, lower the dose \u2014 not raise it.<\/p>\n<\/div>\n

Indikationer och dosering<\/h2>\n\n\n\n\n\n\n\n\n\n
Indikation<\/th>\nStartdos<\/th>\nM\u00e5lgrupp<\/th>\nMax<\/th>\n<\/tr>\n<\/thead>\n
Stor depression<\/td>\n15 mg HS<\/td>\n30 mg HS<\/td>\n45 mg<\/td>\n<\/tr>\n
Depression with insomnia<\/td>\n7.5\u201315 mg HS<\/td>\n15 mg HS (often sufficient)<\/td>\n30 mg<\/td>\n<\/tr>\n
Depression with weight loss \/ anorexia<\/td>\n15 mg HS<\/td>\n30\u201345 mg HS<\/td>\n45 mg<\/td>\n<\/tr>\n
SSRI augmentation<\/td>\n7.5\u201315 mg HS added to SSRI<\/td>\n15 mg HS<\/td>\n30 mg<\/td>\n<\/tr>\n
\u00c4ldre vuxna<\/td>\n7.5 mg HS<\/td>\n15 mg HS<\/td>\n30 mg<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Viktiga s\u00e4kerhets\u00f6verv\u00e4ganden<\/h2>\n
\nWeight gain and metabolic effects<\/strong><\/p>\n

Mirtazapine is one of the heaviest-weight-gain antidepressants \u2014 typical 4\u20137 kg over 6 months. Useful in patients with depression-related weight loss; problematic in obese or metabolic-syndrome patients. Check fasting lipids and HbA1c at 6 months.<\/p>\n<\/div>\n

\nAgranulocytosis (rare)<\/strong><\/p>\n

Reversible neutropenia and rare agranulocytosis described \u2014 incidence approximately 1 in 1000. Stop immediately and check FBC if fever, sore throat, mouth ulcers, or other signs of infection appear in the first 8 weeks.<\/strong> Routine FBC is not required.<\/p>\n<\/div>\n

\nRestless legs and PLM<\/strong><\/p>\n

Mirtazapine commonly worsens restless legs syndrome and periodic limb movements of sleep \u2014 relevant in patients with prior RLS or sleep complaints.<\/p>\n<\/div>\n

\nSj\u00e4lvmordstankar black-box (under 25)<\/strong><\/p>\n

Alla antidepressiva b\u00e4r en FDA black-box-varning f\u00f6r \u00f6kad suicidalitet hos patienter under 25.<\/p>\n<\/div>\n

Vanliga biverkningar<\/h2>\n